It’s looking increasingly likely that Congress will attach a straight reauthorization of FDA user fee programs to a temporary government-funding bill to buy time to negotiate with Sen. Richard Burr (R-NC) over the many bipartisan policy riders that he insists be stripped from the broader user fee bills that moved through the House and the Senate health committee, lobbyists say. It would be the first time that user fee programs were renewed without additional policies since the first of those...